Description
GSK-2334470 is a selective inhibitor of PDK1 that exhibits anticancer activity in in vitro models. GSK-2334470 inhibits T-loop phosphorylation of SGK and S6K1, Akt and Akt substrates GSK3, FoxO, and PRAS40, and ERK substrate RSK2.
| Product Unit Size | Cost | Quantity | Stock |
|---|
GSK-2334470 is a selective inhibitor of PDK1 that exhibits anticancer activity in in vitro models. GSK-2334470 inhibits T-loop phosphorylation of SGK and S6K1, Akt and Akt substrates GSK3, FoxO, and PRAS40, and ERK substrate RSK2.
| Cas No. | 1227911-45-6 |
|---|---|
| Purity | ≥99%, ≥99%ee |
| Formula | C25H34N8O |
| Formula Wt. | 462.59 |
| Chemical Name | (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N-cyclohexyl-6-methylpiperidine-3-carboxamide |
| IUPAC Name | (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N- cyclohexyl-6-methylpiperidine-3-carboxamide |
| Solubility | DMSO 28 mg/mL (64.6 mM) Water Insoluble Ethanol Insoluble |
| Appearance | off-white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Najafov A, Sommer EM, Axten JM, et al. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J. 2011 Jan 15;433(2):357-69. PMID: 21087210.
PLK1 inhibitor.
SIRT1/2 inhibitor.
Macrolide; threonyl-tRNA synthetase/ligase inhi...
ERK1/2 inhibitor.
Benzimidazole; microtubule polymerization inhib...
AhR agonist.
Endogenous pterin coenzyme required for release...
Immunodominant peptide epitope occurring in mul...
Opioid peptide; δOR agonist.
Synthetis peptide, melanocortin analog; MCR ago...
GABA analog; GABA potentiator, adenosine A1 ago...
MEK 1/2 inhibitor.
PERK inhibitor.
Glycopeptide, vancomycin analog; peptidoglycan ...
Smo inhibitor.
SERT and NET inhibitor, Nav1.7 Na+ channel bloc...
Bosutinib isomer; Src and Abl inhibitor.
Triterpene found in Centella, prevents melanoge...
σ2 agonist.
Imidazole; PPARγ agonist, RORγ inverse agonis...